盟科药业
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China 2024-11-29 22:00
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia 2024-10-25 19:29
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum 2024-10-18 22:09
MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections 2024-10-08 13:38
MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference 2024-07-18 13:19
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China 2024-06-06 19:52
First Subject Enrolled in Phase 1 Study of MRX-5 2023-11-20 18:34
MicuRx announces poster presentation and participation in ID Week 2023 Conference 2023-10-11 23:33
MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil 2023-09-22 16:41
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc. 2023-02-08 16:05
China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection 2021-06-03 22:15
1